Gabelli maintained a Buy rating on Lexicon Pharmaceuticals (NASDAQ: LXRX). The stock decline recently after the company said it was ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE